Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Accuracy of diagnostic imaging modalities for peripheral post-traumatic osteomyelitis: a systematic review of the recent literature
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-017-3683-7
document
Post-traumatic osteomyelitis (PTO) is difficult to diagnose and there is no consensus on the best imaging strategy. The aim of this study is to present a systematic review of the recent literature on diagnostic imaging of PTO. A literature search of the EMBASE and PubMed databases of the last 16 years (2000-2016) was performed. Studies that evaluated the accuracy of magnetic resonance imaging (MRI), three-phase bone scintigraphy (TPBS), white blood cell (WBC) or antigranulocyte antibody (AGA) scintigraphy, fluorodeoxyglucose positron emission tomography (FDG-PET) and plain computed tomography (CT) in...
Geertje A Govaert, Frank F IJpma, Martin McNally, Eugene McNally, Inge H Reininga, Andor W Glaudemans
In vitro imaging of bacteria using (18)F-fluorodeoxyglucose micro positron emission tomography
Published in: Scientific Reports
Access to document
10.1038/s41598-017-05403-z
document
Positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose ((18)F-FDG) can be applied to detect infection and inflammation. However, it was so far not known to what extent bacterial pathogens may contribute to the PET signal. Therefore, we investigated whether clinical isolates of frequently encountered bacterial pathogens take up (18)F-FDG in vitro, and whether FDG inhibits bacterial growth as previously shown for 2-deoxy-glucose. 22 isolates of Gram-positive and Gram-negative bacterial pathogens implicated in fever and inflammation were incubated with (18)F-FDG and uptake of (18)F-FDG was assessed by gamma-counting and µPET imaging....
The round table approach in infective endocarditis & cardiovascular implantable electronic devices infections: Make your e-Team come true
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-017-3679-3
Paola A Erba, Gilbert Habib, Andor W J M Glaudemans, Jose M Miro, Riemer H J A Slart
PET in Benign Bone Marrow Disorders
Published in: Seminars in Nuclear Medicine
Access to document
10.1053/j.semnuclmed.2017.02.006
This review aims to describe the current status of benign bone marrow (BM) imaging using PET. BM imaging is important as the BM is not only involved in poiesis of different vital cell lines and. can be affected by primary BM disorders, but it is also frequently affected by several extramedullary diseases. Indications for the use of PET in benign BM disorders are the detection of extramedullary hematopoiesis, evaluation of patients with a discrepancy between BM histology and clinical status, visualizing BM infarctions, location of the optimal site...
Transient thyrotoxicosis during nivolumab treatment
Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.
M. J. van Kooten, G. van den Berg, A. W. J. M. Glaudemans, T. J. N. Hiltermann, H. J. M. Groen, A. Rutgers, T. P. Links